PRESS RELEASE

BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting

Nes Ziona, Israel – February 17, 2014 – BiondVax (TASE: BNDX), developer of a universal flu vaccine, announced today that it will present at the World Health Organization (WHO)'s invitation-only meeting for influenza vaccine experts, which will be held May 5-7, 2014 in Geneva, Switzerland. The conference is part of WHO's Initiative for Vaccine Research and will focus on flu vaccination developments, with the goal of promoting achievement of long term, efficient protection of the global population against a broad array of influenza strains. Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientist, will present the results of BiondVax's various studies and the Company's strategy for pandemic preparedness ahead of flu outbreak, as part of a session on new approaches for broadly protective flu vaccines. Key stakeholders in the global vaccination industry, as well as representatives from regulatory bodies, top tier academic research labs and opinion leaders will also attend the closed meeting.

"We are excited to participate in this important event, which provides the Company with a unique opportunity to present its achievements and pandemic preparedness plans in front of global decision and policy makers in the flu space. Governments and health organizations around the world look to the WHO for guidance about influenza policies and therefore it is critical for the Company's success to be there", said Ron Babecoff, CEO of BiondVax.

This WHO meeting is a closed-door event that is attended only by organizations and companies selectively invited to participate, with just a few participants given the opportunity to present. The topics presented at the conference go through a process of review and selection, and the meeting is reported in a peer-reviewed article. There will be representatives from foundations such as Bill and Melinda gates foundation and the major flu vaccine manufacturers, including Sanofi, GSK, Novartis, Baxter and bioCSL. The pivotal role of the WHO in the influenza arena is indicated by the wealth of programs currently run by this organization, including, Global Influenza Program (GIP), Global Action Plan for Influenza Vaccines (GAP), Strategic Advisory Group of Experts (SAGE) on Immunization Pandemic Influenza Preparedness (PIP) Framework and Global Influenza Surveillance and Response System (GISRS).

About BiondVax Pharmaceuticals Ltd

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving global protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Influenza (flu) is the most common infectious disease, caused by countless flu strains as the virus mutates unpredictably and frequently. Current seasonal and pandemic/pre-pandemic flu vaccines rely predominantly on triggering immunity to variable viral regions and accordingly are strain-specific. The vaccines are manufactured based on global surveillance each season or to prepare for a predicted pandemic threat and are often mismatched to the emerging flu strains. Therefore there is an urgent need for broadly protective flu vaccines especially in the case of pandemics and this is being addressed by BiondVax.

At this point in time, BiondVax's universal flu vaccine (M-001) has several unique competitive advantages: the universal flu vaccine at the most advanced stage of clinical development (4 clinical trials with about 440 people); an excellent safety profile; triggers both arms of our immune defenses, cellular and humoral (antibodies); active without the need for an adjuvant; easily, quickly and cheaply manufactured in only 6-8 weeks (conventional flu vaccines take 6-8 months); can be produced year-round and stockpiled as its composition does not change; and finally, M-001 has two indications, as a universal flu vaccine and as an enhancer of conventional strain-specific seasonal/pandemic flu vaccines. Of note, this second indication provides a shorter and cost-effective pathway for clinical development, regulatory approval and commercialization of M-001 and provides a new approach to pandemic preparedness AHEAD of flu outbreak.

For further information, please contact:
Sharon Levin
Gelbert- Kahana
Tel: +972 3 607 4717
Mob: +972-54-4860339
sharonl@gk-biz.com

שרון לוין
גלברט כהנא
טל: 6074717-3-972+
נייד: 4860339-54-972+

BiondVax`s estimates regarding the future development of the vaccine and expected trials with respect to the vaccine are forward looking information based on the information that BiondVax has in its possession today pertaining to the potential of the vaccine`s development. These estimates may not be realized, in whole or in part, and/or may be realized differently than estimated, as a result of different factors, including the failure to reach the objectives of the trials and/or schedules and/or to obtain the necessary funding for the continuation of development of the vaccine as well as other factors which are not within BiondVax's control and the materialization of any of the risk factors detailed in Section 5.27 of BiondVax`s shelf prospectus published on January 8, 2014.